Impact of indoor residual spraying and insecticide-treated nets on malaria burden in 8 districts in West Nile and Acholi regions, Uganda: a quasi-experimental study Authors: Jane F Namuganga, Daniel P McDermott, Adrienne Epstein, Joaniter I Nankabirwa, Samuel Gonahasa, Jimmy Opigo, Isaiah Nabende, Catherine Maiteki-Sebuguzi, Moses R Kamya, Martin J Donnelly, Grant Dorsey, Sarah G Staedke Published: 2026 ABSTRACT AbstractBackgroundIn Uganda, where malaria transmission is high, insecticide treated nets (ITNs) have been distributed nationwide every 3 years since 2013. In West Nile, northern Uganda, indoor residual spraying (IRS) was first implemented with clothianidin-deltamethrin (Fludora Fusion®) in 2022, followed by pirimiphos-methyl (Actellic® 300CS) in 2023. We utilised a quasi-experimental study to assess the impact of IRS + ITNs on malaria incidence in West Nile.MethodsData were collected from three malaria reference centres (MRCs) in West Nile (IRS + ITNs, intervention) and five MRCs in neighbouring Acholi (ITNs only, control) over 4 years: (1) Baseline (December 2020–November 2022), prior to IRS; (2) IRS-1 (December 2022–December 2023) following IRS with clothianidin-deltamethrin; (3) IRS-2 (January 2024–December 2024) following IRS with pirimiphos-methyl. The primary outcome was monthly malaria incidence from each MRC target area per 1000 person-years. Data were analysed using negative binomial regression models with a difference-in-difference approach, comparing pre-post trends in malaria incidence between arms. Adjusted models accounted for 2-month lagged rainfall and seasonality.ResultsDuring IRS-1, mean observed malaria incidence fell from baseline in both arms (intervention: 720.9 to 547.9; and control: 523.4 to 455.2 per 1000 person-years). We detected a 15% difference in predicted mean incidence between arms during IRS-1 relative to baseline, but this was not significant (adjusted incidence rate ratio (aIRR) = 0.85, 95% confidence interval (CI) 0.69–1.04, p = 0.11). During IRS-2, incidence in the intervention arm declined by 79.3% compared to baseline (720.9 to 149.1), and by 24.3% (523.4 to 396.2) in the control arm. We detected a 73% reduction in predicted mean malaria incidence in the intervention arm compared to control relative to baseline (aIRR = 0.27, 95% CI 0.22–0.34, p < 0.001). During IRS-2, there was strong evidence of an immediate and sustained reduction in incidence in the intervention arm over 1 year.ConclusionsIn West Nile, the reduction in malaria incidence after clothianidin-based IRS (plus ITNs) was modest and non-significant. Subsequent IRS with pirimiphos-methyl (plus ITNs) substantially reduced malaria incidence. These results highlight the importance of selecting context-specific insecticides for vector control programmes and the potential synergistic effect of dual interventions in areas of high pyrethroid resistance.Supplementary InformationThe online version contains supplementary material available at 10.1186/s44263-026-00268-9.Keywords: Malaria, IRS, Clothianidin-deltamethrin , Pirimiphos-methyl, Insecticide-treated nets, Impact of vector control interventions, ITNs Background Despite concerted efforts to eliminate malaria, the global burden remains high, with an increasing trend in incidence observed in some endemic countries since 2015 [1]. Sub-Saharan Africa remains disproportionately affected relative to the rest of the world [1]. Insecticide-treated nets (ITNs) and indoor residual spraying of insecticide (IRS) are the principal vector control tools targeting anopheline mosquitoes that feed and rest indoors [2]. However, their effectiveness is determined by the susceptibility of primary vectors to insecticides, population-level intervention uptake, and intervention coverage [3]. Unfortunately, insecticide resistance remains a major threat to malaria control efforts [1], affecting four of the five major insecticide classes (pyrethroids, carbamates, organophosphates and neonicotinoids) [1, 4, 5]. The World Health Organization (WHO) recommends rotation of IRS insecticides at pre-set intervals, and diversification from pyrethroid insecticides to mitigate the development and spread of resistance [2, 3]. Where pyrethroid resistance is high, replacing standard (pyrethroid-only) nets with new-generation ITNs is encouraged, including pyrethroid plus either piperonyl butoxide (PBO), chlorfenapyr, or pyriproxyfen [2]. Co-deployment of IRS and ITNs is not recommended by WHO [2], but widespread pyrethroid resistance [5] has prompted deployment of these interventions together to reduce malaria transmission in high burden areas [2, 6]. In Uganda, the Ministry of Health (MOH) has adopted rotation of IRS insecticides every 3 years, and the co-deployment strategy in areas hardest hit by malaria. Although globally IRS coverage is low [1], many sub-Saharan African countries have benefited from IRS campaigns over the past two decades [7–15]. In 2018, clothianidin-based products, Sumishield® (clothianidin-only) [16], and Fludora Fusion® (clothianidin-deltamethrin mixture) [17] were adopted and deployed for IRS in several countries, replacing pirimiphos-methyl [8, 10, 11, 13, 14]. Replacement often coincided with country-specific predefined timelines for IRS insecticide rotation and aligned with WHO recommendations for insecticide resistance mitigation [2]. Previously, these insecticides demonstrated prolonged residual efficacy (up to 48 weeks) [18–20], and high vector species susceptibility [18, 19, 21]. Nevertheless, their population-level impact has differed across countries [10–12, 14, 15, 22] underscoring the need for continued assessment of effectiveness in real-world settings. In 2022, clothianidin-deltamethrin-based IRS was deployed in West Nile, Uganda, an area with intense malaria transmission [23]. IRS was repeated in 2023 with pirimiphos-methyl. This rather premature switch in insecticides was prompted by a dramatic malaria resurgence in Eastern Uganda [12, 22]. Additionally, a combination of standard and new-generation ITNs was distributed in 2020/2021 and 2023/2024 during Uganda’s campaigns to distribute long-lasting insecticidal nets (LLINs), presenting an opportunity to evaluate IRS plus ITNs in a high transmission setting. To evaluate the effect of co-deployment of these interventions, we utilised a quasi-experimental, difference-in-differences study of health facility-based surveillance data to compare malaria indicators in West Nile to those in the neighbouring Acholi region that received ITNs but not IRS. Methods Study sites This study was embedded within the Program for Resistance, Immunology, Surveillance and Modelling of Malaria (PRISM) project [24], which conducts enhanced surveillance at selected public health facilities in Uganda. West Nile and Acholi are high transmission regions in northern Uganda [23, 25, 26] (Infectious Diseases Research Collaboration (IDRC): Enhanced Entomological Surveillance (EES) For Malaria Control In Uganda: Comprehensive Activity Report, Unpublished), an area bordering South Sudan, Democratic Republic of Congo (DRC) and Kenya. The regions are separated by the Albert Nile, with West Nile to the west and Acholi to the east. The terrain in both regions is predominantly flat, with tropical climatic conditions comprised of one distinct wet and dry season. The burden of malaria in northern Uganda is high [23, 25]. In the 2019 Malaria Indicator Survey (MIS), parasite prevalence by microscopy in children under 5 years was 22% and 12% in West Nile and Acholi, respectively [23]. Anopheles gambiae s.s. and Anopheles funestus are the primary malaria vectors in Uganda, with An. gambiae s.s. being the predominant species [26] (Uganda Ministry of Health: The Uganda Malaria Reduction and Elimination Strategic Plan 2021–2025, Unpublished). However, IRS implementation prompted a shift in vector species, with An. arabiensis, an outdoor-biting mosquito, becoming more prevalent, particularly in districts with sustained IRS coverage [27]. Where ITNs are the sole vector control measure, An. funestus and An. gambiae s.s. are dominant [28] (Infectious Diseases Research Collaboration (IDRC): Enhanced Entomological Surveillance (EES) For Malaria Control In Uganda: Comprehensive Activity Report, Unpublished), (Uganda Ministry of Health: The Uganda Malaria Reduction and Elimination Strategic Plan 2021–2025, Unpublished). IRS deployment in northern Uganda The Acholi region received IRS from 2009 to 2014 [8]. Deployment of IRS was then halted, with the exception of a single round of IRS with pirimiphos-methyl which was delivered in 2017 in response to a resurgence of malaria [8]. In West Nile, IRS was first introduced in December 2022 with clothianidin-deltamethrin. IRS coverage, defined as the proportion of houses found that were sprayed, averaged 92% (Infectious Diseases Research Collaboration (IDRC): Enhanced Entomological Surveillance (EES) For Malaria Control In Uganda: Comprehensive Activity Report, Unpublished) and 88% [29] in 2022 and 2023, respectively. Mass distribution of ITNs ITNs are Uganda’s primary vector control intervention, distributed through government-sponsored mass distribution campaigns. Between 2013 and 2024, four mass campaigns were conducted countrywide. Standard nets were distributed in the first round (2013/2014). Thereafter, a combination of new-generation ITNs and standard nets were delivered in selected areas during subsequent rounds [27, 30]. In 2019, ITN ownership was 92% and 83%, and net use was 76% and 62% in West Nile and Acholi respectively [23]. In the 2019/2020 mass campaign, selected sub-counties in West Nile and Acholi (including the study sites) received either pyrethroid-PBO or pyrethroid-pyriproxyfen ITNs while the remaining areas received standard, pyrethroid-only nets [27]. All 8 study sites were in sub-counties that received pyrethroid-PBO nets in the 2020/21 campaign and either pyrethroid-PBO (one intervention site and three control sites) or pyrethroid-chlorfenapyr (two intervention and two control sites) nets in the 2023/2024 campaign (Additional File 1: Table S1). Health facility-based surveillance We leveraged an existing malaria sentinel site surveillance network previously managed by the Uganda Malaria Surveillance Project (UMSP) at Malaria Reference Centres (MRCs) and described elsewhere [31]. Surveillance activities are ongoing at 38 high-volume level III/IV public health facilities across Uganda that provide free general medical services to surrounding populations. At each MRC, individual-level outpatient data collected in paper-based health management information system (HMIS) forms are transcribed into an electronic database monthly. A detailed description of data collection, management, analysis and dissemination processes at these sites has been published previously [32]. Selection of target areas for incidence measurements A target area (Additional File 1: Fig. S1) was defined as the village where the MRC is located and adjacent villages that lack another health facility, are within the same sub-county, have similar malaria incidence, and together have an estimated population of at least 1,500 persons. These were 1–7 villages around each MRC from where at least 90% of patients that sought care from each site resided and were identified using at least 6 months’ data from each MRC (collected between November 2018 and November 2019). Enumeration surveys were conducted to estimate the population of each target area. These estimates serve as the denominator for incidence measures for each target area, considering a fixed population growth rate of 0.29% per month. This approach is described in detail elsewhere [27, 32, 33]. Site selection This study included eight MRCs (Fig. 1), three in West Nile (intervention) and five in the Acholi region (control). All MRC sites within West Nile were included as intervention sites. Control sites were selected from the adjacent Acholi region (with similar malaria endemicity, climate and geographical conditions) using the following criteria: (1) within the Acholi region; (2) 2 years of individual-level data available from December 2020 to December 2022; (3) received pyrethroid-PBO ITNs (PermaNet® 3·0) in 2020/2021, and either pyrethroid-PBO or pyrethroid-chlorfenapyr (PermaNet® Dual) nets in 2023. Geographical location of study sites Defining IRS periods (independent variables) The study was divided into three follow-up periods: (1) baseline, defined as the 24-month period before IRS was implemented in West Nile (December 2020 to November 2022); (2) IRS-1, the 13-month period following deployment of clothianidin-deltamethrin (Fludora Fusion®) in West Nile (December 2022 to December 2023); and (3) IRS-2, the 12-month period following IRS with pirimiphos-methyl (Actellic® 300CS) in West Nile (January 2024 to December 2024). For our analysis, the independent variable was the IRS period, specified as a categorical variable representing the first (IRS-1) and second (IRS-2) periods. Outcome measures The dependent variable for the primary analyses was site-specific monthly estimates of malaria incidence, defined as the number of laboratory-confirmed malaria cases from the target area of each MRC per 1000-person years of observation. We corrected for variation in monthly testing rates to account for missed testing during commodity stock-outs by multiplying the number of patients with suspected malaria but not tested by the test positivity rate (defined as the proportion of patients with laboratory-confirmed malaria of all patients tested for malaria). Results remained consistent with and without this correction. The result was then added to the number of confirmed malaria cases in that month. The study arm was specified as a categorical variable denoting the intervention and control arms. Statistical analysis To evaluate the impact of IRS in the West Nile region, we employed a difference-in-differences (DID) approach, which compared pre-post trends in malaria incidence after the implementation of IRS in intervention groups to the average pre-post change in the control group [34]. The outcome model for our DID was as follows: where Yit is the outcome (malaria incidence) per MRC i in month t, β0 is the intercept—the average outcome for the control arm at baseline, β1 is the average difference between the intervention and control arms before the intervention, Treati is a binary variable representing whether a site is in the treatment or control arm, and β2 is the overall change over time from baseline in the control arm. Postit is a categorical variable representing the treatment period (pre-IRS, IRS-1, and IRS-2), and Xit represents a vector of site- and time-varying covariates. β3 is the key DID parameter in this model which represents the treatment effects of IRS-1 and IRS-2 periods on malaria incidence and β4 is the effect of the covariates on malaria incidence. εit is an error term capturing unobserved determinants of malaria incidence. DID analyses, which are formal comparisons of slopes, were implemented using generalised linear mixed models using the negative binomial distribution and random intercepts for site. The outcome for this model was the MRC-level monthly count of malaria cases in the target area, with an offset for the target area population. Model coefficients were exponentiated into incidence rate ratios (IRR) representing the treatment effect for each IRS period relative to the baseline period. We adjusted for seasonality and 2-month lagged rainfall. Seasonality was specified as a factor variable denoting the rainy (March to May and September to November every year) and dry (December to February and June to August every year) seasons. Rainfall data were retrieved from the Climate Hazards Group Infrared Precipitation with Station data (CHIRPS) database [35]. These were extracted as monthly site-specific estimates in millimetres for each study site. Adjusted models included a categorical variable for seasonality and a continuous variable for monthly site-level 2-month lagged rainfall estimates (in millimetres). To produce valid estimates, DID relies on the assumption of parallel trends, which states that the average trend of the treated and control groups would have been parallel in the absence of the intervention [34]. While this assumption is formally untestable, parallel trends were assessed in the pre-IRS period to ensure the pre-intervention trends met these criteria. This was done by restricting the model to the pre-IRS period and including an interaction term between treatment arm (binary) and a linear time trend in months, with the same covariates as the primary DID analysis and checking if the slopes were significantly different. We used Stata version 18.5 (StataCorp LLC, College Station, TX, USA) statistical software to clean data and generate aggregate monthly estimates for key variables including malaria incidence estimates. Further cleaning, analysis, and model fitting to generate tables and graphs was performed in R (version 4.4.0) using the glmmTMB and lme4 packages. All datasets and analytic code used for the analysis are available on Github [36]. Additionally, a Transparent Reporting of Evaluations with Nonrandomized Designs (TREND) checklist of our paper was completed (Additional File 2). Results Descriptive characteristics Overall, 118,916 outpatient visits were recorded for residents from the 8 MRC target areas (Table 1), including 61,828 visits during the 24-month baseline period, 30,229 during the 13-month period following deployment of clothianidin-deltamethrin (IRS-1), and 26,859 visits during the 12-month period following deployment of pirimiphos-methyl (IRS-2). The median age of patients was 15 years (interquartile range (IQR) 4.5–25.2), and two-thirds were female (77,547 (65.2%)). In total, 88,999 (74.8%) patients were suspected to have malaria, of whom 88,033 (98.9%) were tested using either a malaria rapid diagnostic test (RDT) or microscopy. Confirmatory testing for malaria was predominantly done with RDTs (77,787 (88%)) (Additional File 1: Fig. S2). Table 1Target area-specific statistics stratified by MRC, study arm and study periodStudy periodRegionStudy armMRC (district)Outpatient visitsMedian age (IQR)Female sex n (%)Suspected malaria cases n (% outpatient visits)Suspected cases tested n (%)Confirmatory testing by RDT n (%)Confirmed malaria cases n (% (TPR))Mean malaria incidence per 1000 person-years of observationBaseline (24-month period pre-IRS with Fludora Fusion)West NileInterventionAyipe HCIII (Koboko)931612 (2.0–22.0)5814 (62.4)8423 (90.4)7848 (93.2)7429 (94.7)5320 (67.8)873Metu HCIII (Moyo)845816 (6.0–26.0)5299 (62.7)6217 (73.5)6182 (99.4)5527 (89.4)3425 (55.4)733Opia HCIII (Arua)825913 (4.5–21.5)5293 (64.1)6992 (84.7)6982 (99.9)6914 (99)4120 (59)557Intervention arm estimates26,03314 (4.5–23.5)16,406 (63)21,632 (83.1)21,012 (97.1)19,870 (94.6)12,865 (61.2)721AcholiControlAtiak HCIV (Amuru)599013 (2.5–23.5)3935 (65.7)4262 (71.2)4262 (100)3702 (86.9)2862 (67.2)385Awach HCIV (Gulu)934015 (3.5–26.4)6495 (69.5)6349 (68)6020 (94.8)5242 (87.1)3722 (61.8)733Namokora HCIV (Kitgum)519215 (2.5–27.5)3306 (63.7)3594 (69.2)3594 (100)2723 (75.8)2094 (58.3)644Padibe HCIV (Lamwo)844417 (6.5–27.5)5301 (62.8)6089 (72.1)6087 (100)5967 (98)3622 (59.5)474Patongo HCIII (Agago)682916 (5.5–26.5)4559 (66.8)5657 (82.8)5657 (100)5289 (93.5)2961 (52.3)381Control arm estimates35,79515 (3.5–26.5)23,596 (65.9)25,951 (72.5)25,620 (98.7)22,923 (89.5)15,261 (59.6)523IRS-1 (13-month period post 1 st IRS round with Fludora Fusion)West NileInterventionAyipe HCIII (Koboko)382812 (3.0–21.0)2590 (67.7)3663 (95.7)3663 (100)3489 (95.2)2228 (60.8)602Metu HCIII (Moyo)482514 (5.0–23.0)3079 (63.8)3763 (78)3763 (100)3043 (80.9)1906 (50.7)712Opia HCIII (Arua)380614 (5.0–23.0)2413 (63.4)3130 (82.2)3128 (99.9)2559 (81.8)1399 (44.7)331Intervention arm estimates12,45913 (4.5–21.5)8082 (64.9)10,556 (84.7)10,554 (100)9091 (86.1)5533 (52.4)548AcholiControlAtiak HCIV (Amuru)290115 (2.5–27.5)1896 (65.4)1831 (63.1)1829 (99.9)1299 (71)1239 (67.7)289Awach HCIV (Gulu)459815 (3.5–26.5)3056 (66.5)3213 (69.9)3204 (99.7)3027 (94.5)1965 (61.3)635Namokora HCIV (Kitgum)276716 (3.5–28.5)1777 (64.2)1962 (70.9)1960 (99.9)1724 (88)1126 (57.4)605Padibe HCIV (Lamwo)367617 (6.5–27.5)2351 (64)2546 (69.3)2546 (100)2135 (83.9)1524 (59.9)349Patongo HCIII (Agago)382817 (6.5–27.5)2514 (65.7)3211 (83.9)3211 (100)2652 (82.6)1757 (54.7)397Control arm estimates17,77016 (4.5–27.5)11,594 (65.2)12,763 (71.8)12,750 (99.9)10,837 (85)7611 (59.7)455IRS-2 (12-month period post 2nd IRS with ActellicWest NileInterventionAyipe HCIII (Koboko)327413 (2.5–23.5)2216 (67.7)3091 (94.4)3091 (100)2977 (96.3)694 (22.5)197Metu HCIII (Moyo)305717 (5.5–28.5)1903 (62.3)1998 (65.4)1998 (100)1615 (80.8)428 (21.4)168Opia HCIII (Arua)279716 (4.5–27.5)1806 (64.6)1889 (67.5)1889 (100)1781 (94.3)335 (17.7)83Intervention arm estimates912815 (4.0–26.0)5925 (64.9)6978 (76.4)6978 (100)6373 (91.3)1457 (20.9)149AcholiControlAtiak HCIV (Amuru)284917 (4.0–20.0)1941 (68.1)1418 (49.8)1418 (100)994 (70.1)794 (56)194Awach HCIV (Gulu)501317 (4.6–29.5)3477 (69.4)2833 (56.5)2833 (100)1983 (70)1460 (51.5)494Namokora HCIV (Kitgum)320014.5 (2.5–26.5)2056 (64.3)2276 (71.1)2276 (100)1847 (81.2)1210 (53.2)682Padibe HCIV (Lamwo)422119 (8.5–29.5)2841 (67.3)2713 (64.3)2713 (100)2474 (91.2)1494 (55.1)359Patongo HCIII (Agago)244816 (5.5–26.5)1629 (66.5)1879 (76.8)1879 (100)1395 (74.2)1063 (56.6)251Control arm estimates17,73117 (5.5–28.5)11,944 (67.4)11,119 (62.7)11,119 (100)8693 (78.2)6021 (54.2)396Total118,91615 (4.5–25.2)77,547 (65.2)88,999 (74.8)88,033 (98.9)77,787 (88.4)48,748 (55.4)497IRS-1: first IRS period 13 months post-IRS with Fludora Fusion; IRS-2: second IRS period 12 months post-IRS with Actellic; IRS indoor residual spraying, MRC malaria reference centre, HCIII health centre III, HCIV health centre IV, RDT rapid diagnostic test, TPR test positivity rate, IQR interquartile range Target area-specific statistics stratified by MRC, study arm and study period IRS-1: first IRS period 13 months post-IRS with Fludora Fusion; IRS-2: second IRS period 12 months post-IRS with Actellic; IRS indoor residual spraying, MRC malaria reference centre, HCIII health centre III, HCIV health centre IV, RDT rapid diagnostic test, TPR test positivity rate, IQR interquartile range Baseline period During the baseline period, malaria was suspected in 21,632 (83.1%) of 26,033 outpatient visits from the intervention arm vs 25,951 (72.5%) of 35,795 visits from the control arm. Of patients tested for malaria, 12,865 of 21,012 in the intervention arm were confirmed positive (test positivity rate (TPR) 61.2%) versus 15,261 of 25,620 in the control arm (TPR 59.6%, Table 1). Observed mean malaria incidence in the intervention arm was 720.9 malaria cases per 1000 person-years (standard deviation (SD) 306.7) and 523.4 malaria cases per 1000 person-years (SD 261.1) in the control arm (Table 2). Monthly observed mean incidence was consistently higher in the intervention arm than in the control throughout the baseline period. Parallel trend analysis detected no difference in the slope of malaria incidence trends between arms at baseline (adjusted incidence rate ratio (aIRR) = 1.00. 95% confidence interval (CI) 0.98–1.01, p = 0.658). Table 2Difference-in-difference coefficients and malaria incidence estimates between study arms in the pre- and post-IRS periodsTime-periodStudy armMalaria incidence per 1000 person-years of observationObserved (SD)Unadjusted estimatesAdjusted estimatesdPredicted, 95% CIDID IRR (95% CI)P valuePredictedDID IRR (95% CI)P valueBaselineaControl523.4 (261.1)529.1 (462.6–605.2)529.4 (455.1–616.1)Intervention720.9 (306.7)731.9 (634.9–843.8)739.6 (634.0–862.9)IRS-1b (13 months post IRS with Fludora Fusion)Control455.2 (263.2)455.8 (391.3–530.9)ReferenceReference449.8 (385.6–524.7)ReferenceReferenceIntervention547.9 (281.1)540.3 (456.1–640.1)0.86 (0.69–1.06)0.16536.3 (452.8–635.3)0.85 (0.69–1.04)0.11IRS-2c (12 months post IRS with Actellic)Control396.2 (237.5)380.6 (325.9–444.6)ReferenceReference382 (326.0–448.4)ReferenceReferenceIntervention149.1 (100.6)145.3 (121.5–173.9)0.28 (0.22–0.35)< 0.001150.8 (125.3–181.4)0.27 (0.22–0.34)< 0.001IRS indoor residual spraying, SD standard deviation, CI confidence interval, DID difference-in-difference, IRR incidence rate ratioaBaseline period: December 2020–November 2022, 24 monthsbIRS-1: December 2022–December 2023, 13 monthscIRS-2: January 2024–December 2024, 12 monthsdAdjusted for site-specific monthly rainfall lagged by 2-months, and seasonality Difference-in-difference coefficients and malaria incidence estimates between study arms in the pre- and post-IRS periods IRS indoor residual spraying, SD standard deviation, CI confidence interval, DID difference-in-difference, IRR incidence rate ratio aBaseline period: December 2020–November 2022, 24 months bIRS-1: December 2022–December 2023, 13 months cIRS-2: January 2024–December 2024, 12 months dAdjusted for site-specific monthly rainfall lagged by 2-months, and seasonality Impact of IRS with clothianidin-deltamethrin (IRS-1) During the 13-month period following IRS with clothianidin-deltamethrin (December 2022 to December 2023), malaria was suspected in 10,556 (84.7%) of 12,459 outpatient visits from the intervention arm versus 12,763 (71.8%) of 17,770 visits from the control arm (Table 1; Additional File 1: Fig. S2). Malaria was diagnosed in 5533 of intervention patients (TPR 52.4%) and 7611 of control patients (TPR 59.7%). A 57% reduction in confirmed malaria case-counts was observed in the intervention arm relative to baseline, corresponding to 7332 confirmed malaria cases averted. Similarly, confirmed cases in the control arm reduced by 50.1% relative to baseline, corresponding to 7650 malaria cases averted. In the intervention arm, TPR declined by 9% from baseline during IRS-1, while TPR in the control arm remained stable (Table 1; Additional File 1: Fig. S3). An overall decline in mean TPR was observed in both arms relative to baseline (Additional File 1: Fig. S3B). In the intervention arm, an immediate decline in TPR was observed within the first 3 months of IRS-1 (December 2022 to February 2023). Thereafter, TPR increased and remained high throughout the remaining 10 months (March 2023 to December 2023). A similar reduction in TPR trends was observed in the control arm, mirroring trends in the intervention arm throughout this period (Additional File 1: Fig. S3B). Mean observed incidence in the intervention arm declined by 24% from 720.9 (SD 306.7) per 1000 person-years at baseline to 547.9 (SD 281.1) during IRS-1. Concurrently, incidence in the control arm declined by 13% from 523.4 (SD 261.1) per 1000 person-years at baseline to 455.2 (SD 263.2) during this period. Using adjusted models (Table 2), we detected a 15% difference in predicted mean malaria incidence between the intervention and control arms relative to baseline, but there was no evidence that predicted incidence differed between arms during IRS-1 (aIRR 0.85, 95% CI 0.69–1.04, p = 0.11). Monthly adjusted IRR estimates showed no difference in mean incidence between study arms following IRS with clothianidin-deltamethrin (Table 3, Fig. 3). Trends in mean malaria incidence during IRS-1 were like those observed for TPR, initially declining over 5 months from December 2022 to April 2023, then increasing and remaining high throughout the next 7 months (May 2023 to December 2023, Fig. 2 and Additional File 1: Fig. S3A). Incidence was consistently higher in the intervention arm than the control throughout this period (Fig. 2). There were 9300 malaria cases averted per 100,000 population during this period. Table 3Monthly adjusted difference-in-difference coefficients and predicted mean incidence by study arm during IRS-1 and IRS-2 periodsIntervention periodMonth and yearPredicted mean malaria incidence per 1000 person-years of observation (95% CI)aIRR (95% CI)P valueIntervention armControl armIRS-1 (13-month period following IRS with clothianidin-deltamethrin)Dec-22576.9 (489.2–680.2)477.3 (411.2–554.0)0.86 (0.52–1.44)0.58Jan-23556.5 (471.8–656.4)484.8 (417.3–563.1)0.82 (0.49–1.36)0.44Feb-23486.1 (409.0–577.7)413.6 (353.7–483.7)0.74 (0.44–1.24)0.25Mar-23396.7 (331.1–475.2)338.7 (287.1–399.6)1.20 (0.71–2.02)0.49Apr-23401.3 (335.5–480.1)341.6 (289.8–402.6)1.54 (0.91–2.60)0.11May-23515.7 (436.4–609.5)451.5 (387.4–526.1)0.96 (0.58–1.60)0.88Jun-23589.7 (499.7–695.9)503.8 (433.8–585.3)0.89 (0.54–1.48)0.66Jul-23566.8 (480.6–668.5)437.7 (375.9–509.6)0.71 (0.43–1.18)0.19Aug-23650.0 (548.0–770.9)554.3 (474.3–647.7)0.89 (0.54–1.47)0.64Sept-23490.6 (415.6–579.0)429.4 (369.1–499.4)0.71 (0.43–1.17)0.18Oct-23522.5 (442.5–617.0)422.0 (362.8–490.8)1.02 (0.62–1.69)0.94Nov-23533.0 (451.0–629.9)436.1 (374.8–507.4)0.60 (0.36–0.99)0.05Dec-23686.8 (576.4–818.3)556.3 (475.3–651.1)0.80 (0.48–1.32)0.37IRS-2 (12-month period following IRS with Actellic)Jan-24176.8 (147.6–211.7)383.9 (329.1–447.8)0.38 (0.23–0.63)< 0.01***Feb-24123.6 (102.5–149.1)338.5 (288.1–397.6)0.42 (0.25–0.72)< 0.01***Mar-24109.6 (91.0–132.1)294.8 (250.5–346.9)0.52 (0.30–0.87)0.01***Apr-24118.4 (99.0–141.7)318.1 (272.0–371.9)0.39 (0.23–0.68)< 0.01***May-24119.8 (100.2–143.3)326.0 (279.2–380.6)0.25 (0.15–0.42)< 0.001***Jun-24136.0 (113.8–162.6)401.6 (344.8–467.8)0.25 (0.15–0.42)< 0.001***Jul-24149.0 (125.1–177.4)383.4 (329.2–446.6)0.16 (0.09–0.27)< 0.001***Aug-24172.3 (144.1–206.1))416.5 (357.0–485.9)0.20 (0.12–0.34)< 0.001***Sept-24163.7 (135.7–197.3)470.6 (392.6–564.2)0.24 (0.14–0.42)< 0.001***Oct-24180.7 (148.0–220.7)433.8 (366.9–513.0)0.19 (0.11–0.33)< 0.001***Nov-24176.9 (145.1–215.7)374.9 (321.0–437.8)0.15 (0.09–0.26)< 0.001***Dec-24182.2 (151.6–219.0)445.8 (381.6–520.9)0.19 (0.11–0.32)< 0.001***IRS: indoor residual spraying; IRS-1: December 2022–December 2023, 13 months; IRS-2: January 2024–December 2024, 12 months; aIRR adjusted incidence rate ratio, CI confidence interval Monthly adjusted difference-in-difference coefficients and predicted mean incidence by study arm during IRS-1 and IRS-2 periods IRS: indoor residual spraying; IRS-1: December 2022–December 2023, 13 months; IRS-2: January 2024–December 2024, 12 months; aIRR adjusted incidence rate ratio, CI confidence interval Monthly adjusted difference-in-difference IRR estimates for the interaction between the 1st and 2nd IRS periods and study arm Trends in predicted mean malaria incidence stratified by study arm Impact of IRS with pirimiphos-methyl (IRS-2) During the 12-month period following IRS with pirimiphos-methyl (January 2024 to December 2024), malaria was suspected in 6978 (76.4%) of 9,128 intervention outpatient visits, and 11,119 (62.7%) of 17,731 control outpatient visits (Table 1, Additional File 1: Fig. S1). Malaria was confirmed in 1457 intervention patients (TPR 20.9%) versus 6,021 control patients (TPR 54.2%). An 88.7% reduction in confirmed malaria case-counts was observed in the intervention arm relative to baseline, corresponding to 11,408 confirmed malaria cases averted (Table 1). Confirmed malaria cases in the control arm declined by 60.5%, corresponding to 9240 cases averted in this period relative to baseline (Table 1). Mean TPR declined by 40.3% in the intervention arm but only reduced by 5.4% in the control arm (Table 1). An immediate and substantial drop in mean TPR was observed in the intervention arm within the first 3 months of IRS-2 (January 2024 to March 2024), which was sustained over the remaining 9 months (April 2024 to December 2024) with minor seasonal peaks. In the control arm, a modest decline in TPR occurred in the first 4 months (January 2024 to April 2024). Thereafter, TPR increased and remained high for the remainder of IRS-2 (May 2024 to December 2024) (Additional File 1: Fig. S3A). In the intervention arm, observed mean incidence declined by 79.3% during IRS-2 from 720.9 cases per 1000 person-years (SD 306.7) at baseline to 149.1 (SD 100.6) during IRS-2. In the control arm, observed mean incidence declined by 24.3% from 523.4 (SD 261.1) cases per 1000 person-years at baseline to 396.2 (SD 237.5) during this period (Tables 1 and 2). Model adjustment estimated a 73% reduction in predicted mean malaria incidence in the intervention arm compared to control relative to baseline (aIRR 0.27, 95% CI 0.22–0.34, p < 0.001). Further stratification by month revealed a 62% reduction in incidence in the intervention arm within the first month (January 2024) following IRS with pirimiphos-methyl (aIRR = 0.38, 95% CI 0.23–0.63, p < 0.01) (Table 3; Fig. 3). The reduction in incidence in the intervention arm was sustained until the twelfth month, with an 81% reduction detected in December 2024 (12-month aIRR = 0.19, 95% CI 0.11–0.32, p < 0.001) (Table 3; Fig. 3). No seasonal peaks in malaria incidence were observed in the intervention arm during IRS-2 (Additional File 1: Fig. S3B; Fig. 2). Incidence trends for the control arm during this period were similar to TPR trends, with an immediate decline that lasted 3 months (January 2024 to March 2024). Thereafter, incidence in the control arm peaked and remained high until December 2024 (Additional File 1: Fig. S3B; Fig. 2). A total of 34,800 malaria cases per 100,000 population were averted during this period. To adjust for differences in healthcare-seeking behaviour between arms, we considered using incidence of care-seeking for non-malarial illnesses as a proxy, but sensitivity analysis using a placebo DiD with this variable as the outcome revealed statistically significant reductions in the intervention arm across both periods (IRS-1: aIRR = 0.72, 95% CI 0.60–0.86, p < 0.001; IRS-2: aIRR = 0.65, 95% CI 0.54–0.78, p < 0.001). Nevertheless, including this proxy indicator did not change our primary findings during IRS-1 (aIRR = 0.85, 95% CI 0.69–1.05, p = 0.138) and minimally altered them from a 73% to a 71% reduction in IRS-2 (aIRR = 0.29, 95% CI 0.23–0.36, p < 0.001). Discussion Assessing the impact of population-level vector control interventions is critical for tracking progress in malaria control and guiding future deployment strategies. In this study, enhanced health facility-based surveillance data were analysed to estimate the combined impact of ITNs and IRS with two insecticides, clothianidin-deltamethrin and pirimiphos-methyl, on malaria incidence in West Nile, Uganda, as compared to ITNs without IRS in the Acholi region. We found no significant difference in predicted incidence in the 13 months following initial IRS with clothianidin-deltamethrin compared to control. In contrast, an immediate, substantial and sustained reduction in malaria incidence was observed when IRS with pirimiphos-methyl was deployed in the subsequent year. These findings suggest that IRS with pirimiphos-methyl (plus ITNs) was markedly more effective than IRS with clothianidin-deltamethrin in northern Uganda. Clothianidin-based IRS for malaria control has generated mixed results across sub-Saharan Africa. Entomological studies assessing insecticide efficacy with WHO tube tests and bottle bioassays, and CDC bottle bioassays [3], have generally yielded positive results for clothianidin [18, 19, 21, 37–40]. However, findings from these assessments may over-estimate actual field effectiveness; further validation with results from epidemiological studies is needed [10, 11, 15]. Our findings are consistent with other studies conducted in eastern Uganda, where a switch from pirimiphos-methyl to clothianidin-based IRS was associated with an eightfold increase in malaria incidence and a fourfold increase in parasite prevalence [12, 22]. Similarly, a study in Zambia [15], using routine surveillance data, found that transitioning from pirimiphos-methyl to clothianidin-deltamethrin did not reduce parasite prevalence. In Côte d’Ivoire [11], an analysis of routine surveillance data was undertaken to determine incidence changes in IRS vs non-IRS districts following the introduction of clothianidin-based IRS. This study found that the month-to-month incidence trend did not change in either area after the initial round, monthly malaria cases increased at a rate 2.5× higher than in non-IRS areas, and following the second IRS round a significantly higher increase in cases was observed in IRS areas vs control [11]. In Burkina Faso, another epidemiological study utilising routine surveillance data found that the impact of clothianidin-based IRS on malaria case rates varied by region [10]. Where reductions in malaria case rates were observed, they were only modest, diminished with each round, and hardly differed from those observed in non-IRS areas [10]. Taken together, these studies suggest that clothianidin was ineffective. In contrast, an evaluation of IRS in Madagascar [14], including IRS with clothianidin-based insecticides, yielded positive results. Here, IRS was associated with a 30% reduction in incidence, with incremental reductions in subsequent years. However, this study did not disaggregate IRS impact by insecticide type, rendering it difficult to attribute these positive findings solely to clothianidin-based IRS. The lack of effectiveness of clothianidin-deltamethrin in West Nile could be attributed to multiple factors including insecticide resistance, shifts in vector species composition, housing quality, and the timing and quality of spraying. High-level pyrethroid resistance [41–44] and high clothianidin tolerance [44] both exist in Uganda. Predominant malaria vectors in Uganda are resistant to deltamethrin [42, 45, 46], rendering it generally ineffective. In 2016–2017, signs of clothianidin resistance in wild mosquito species were detected in Uganda [18], prior to the WHO prequalification of clothianidin-based insecticides for IRS. Other studies have since confirmed that while clothianidin generally remains effective in most settings, susceptibility patterns vary among wild mosquito populations [26, 46–48]. More recently, waning mortality rates for An. funestus were observed following IRS with clothianidin-based insecticides in eastern Uganda [46, 47]. Clothianidin resistance could have resulted from widespread use of neonicotinoid-containing pesticides in agriculture in Uganda [48]. High concentrations of neonicotinoids have been detected in waterbodies [49], groundwater in non-IRS areas [50], on fresh fruits and vegetables [51], and in honeybee products [52] in Uganda. Neonicotinoid insecticides are hydro-soluble, persisting in surface water, including in potential breeding sites for mosquito larvae, and exceedingly high concentrations beyond regulatory thresholds have previously been detected in African settings [49]. However, attempts to confirm this hypothesis in West Africa have yielded mixed results. Neonicotinoid use in agriculture was found to reduce wild mosquito vector susceptibility to clothianidin in Cameroon [53, 54], but not in Benin [40], and while wild vectors collected from agricultural settings in Cameroon demonstrated lower mortality on exposure to clothianidin [54], susceptibility remained high for wild An. gambiae s.s. from 18 agricultural settings in Benin [40]. These mixed results underscore the need to guide deployment of clothianidin-based IRS on resistance patterns of local vectors [2]. Shifts in predominant malaria vector species, documented elsewhere in Uganda, may also have reduced the effect of clothianidin-deltamethrin [22]. Historically, An. gambiae s.s. was the principal malaria vector in Uganda, with smaller populations of An. funestus and An. arabiensis [55]. With deployment of vector control interventions, An. gambiae s.s. and An. funestus populations reduced in regions receiving IRS and ITNs, while An. arabiensis and An. funestus populations markedly, although relatively increased in districts receiving ITNs only (not IRS) [9, 28, 46, 55] (Infectious Diseases Research Collaboration (IDRC): Enhanced Entomological Surveillance (EES) For Malaria Control In Uganda: Comprehensive Activity Report, Unpublished). This pattern was also observed in Eastern Uganda following several years of sustained IRS with carbamates, organophosphates, and neonicotinoids [55], where both An. gambiae s.s. and An. funestus populations reduced and were initially replaced by An. arabiensis. More recently, however, An. funestus populations have been restored [22, 46, 47, 55]. Although An. arabiensis remained highly susceptible to clothianidin, An. funestus has exhibited high tolerance [22]. A similar shift occurred in West Nile between 2021 and 2023 when the proportion of field-collected An. funestus increased markedly from 0–7% before IRS with Fludora® Fusion, to 69–80% after, while those of An. gambiae s.s. reduced from 93–100% to 18–31% (Infectious Diseases Research Collaboration (IDRC): Enhanced Entomological Surveillance (EES) For Malaria Control In Uganda: Comprehensive Activity Report, Unpublished). The evidence suggests that An. funestus was likely the dominant vector in West Nile in 2022 and 2023, which may not have been susceptible to the clothianidin-based insecticides. Entomological surveillance conducted in 2023 in West Nile revealed that field-collected An. funestus species from this region had 50% higher sporozoite rates, and 30× higher indoor human biting rates than An. gambiae, demonstrating higher propensity to transmit malaria [22] (Infectious Diseases Research Collaboration (IDRC): Enhanced Entomological Surveillance (EES) For Malaria Control In Uganda: Comprehensive Activity Report, Unpublished). Coupled with the higher tolerance of An. funestus to clothianidin, the lack of impact following IRS with clothianidin-deltamethrin in West Nile is not surprising. Housing quality in West Nile may also have reduced the effectiveness of clothianidin-deltamethrin. Traditionally constructed housing, characterised by mud walls, thatch roof and open eaves is highly prevalent in northern Uganda [33]. Clothianidin is known to exhibit lower mortality and residual efficacy when applied to mud walls as compared to cement [18, 20, 21], presumably due to the high porosity of mud [56]. Incorporating cement substrate within mud bricks has been shown to markedly improve clothianidin’s residual efficacy close to levels observed on cement [38]. In eastern Uganda, concentrations of clothianidin on sprayed walls were below the target dose, while excess concentrations of pirimiphos-methyl were detected [47]. These differences could be attributed to inadequate deployment, especially where differences in spray operations exist, but the same teams delivered IRS in these areas, making variability in implementation less likely. Timing of IRS deployment, at the start of the long dry season, is counter to WHO’s recommendation and may also have reduced the impact of clothianidin-deltamethrin as concentrations of the insecticides may have dwindled long before the start of the peak transmission season. We found that pirimiphos-methyl performed exceptionally well in West Nile, substantially reducing malaria incidence when deployed 1 year after the single round of clothianidin-deltamethrin. Historically, pirimiphos-methyl has been highly effective in Uganda, with the 3-year period of sustained IRS providing the greatest malaria control [8, 12, 22, 57]. Other African countries have documented remarkable results following IRS with pirimiphos-methyl. In Benin, one round of IRS with pirimiphos-methyl was associated with 7.5× lower biting rates, 75% reduction in vector density, and 34% reduction in blood feeding rates compared to control, which was consistent through subsequent IRS rounds [37, 58]. Similar results were observed in Kenya when entomological monitoring conducted before and after IRS with pirimiphos-methyl found an 88% and 93% reduction in field-collected An. funestus vector species by light traps and pyrethrum spray catches (PSC) respectively, and a 69% reduction in field-collected An. arabiensis [7]. In this same study, sporozoite infections and human biting rates were reduced to nearly zero. Conversely, pirimiphos-methyl conferred only modest reductions in incidence (9–25%) in Zambia [13], and malaria case rates increased when a round of pirimiphos-methyl was implemented following three rounds of clothianidin-based IRS in Burkina Faso [10]. Why was pirimiphos-methyl more effective for IRS in West Nile? Relative to clothianidin-deltamethrin, it is faster-acting [18, 19, 37, 59], exhibiting an immediate and much stronger lethal effect (nearly 2.5× higher) within 24 h [59]. In contrast, clothianidin-deltamethrin requires at least 5 days to attain similar results [19, 56, 59, 60]. Moreover, pirimiphos-methyl’s residual efficacy extends at least 10 months [61], with some variation by location and type of wall substrate [62–64], providing protection against malaria throughout the transmission season and allowing for annual deployment. Importantly, pirimiphos-methyl has remained highly efficacious against all mosquito vector species in Uganda, including An. funestus [46, 65]. Wild An. gambiae vector species in Burkina Faso, Togo, and Benin also remain highly susceptible to pirimiphos-methyl despite high resistance to DDT, pyrethroids and bendiocarb [18, 21, 37, 61, 66]. Levels and prevalence of organophosphate resistance remain either low or largely undetermined globally [5], but resistance is emerging within sub-Saharan Africa [67, 68]. This may explain why in Burkina Faso, a single IRS round with pirimiphos-methyl following multiple rounds with clothianidin-based IRS was associated with an increase in malaria case rates [10]. Also, like neonicotinoids, organophosphates are also widely used in agriculture [51, 52] and continued exposure to sub-lethal doses will potentially increase selection pressure for resistant malaria vectors. Continued investment in entomological surveillance monitoring and related insecticide resistance research is critical. Our study had several strengths. We applied a quasi-experimental study design to assess IRS impact in West Nile using enhanced health facility-based surveillance data, providing a cost-effective means for population-level impact evaluation. Including data from control health facilities located in the neighbouring Acholi region with similar climatic and geographic conditions allowed us to disaggregate incidence changes unrelated to IRS from those associated with IRS. Additionally, we utilised individual-level data from our MRC sentinel site surveillance system where monthly quality assurance checks ensured high quality data. However, our study also had some limitations. First, our study arms were unbalanced because only a limited number of sentinel sites existed within IRS districts in West Nile. However, we believe that ensuring high quality data from our MRC sites outweighed any potential benefit of expanding to sites outside of our MRC surveillance system. Second, it was impossible to dissociate the impact of IRS from the effect of ITNs. To counter this, intervention and control sites were matched based on ITN type and timing of distribution campaigns, and any bias introduced would be likely to have underestimated the impact of IRS as next-generation ITNs may be more effective than PBO ITNs. Third, we could not appropriately account for changes in care-seeking behaviour during intervention periods due to lack of data. Conclusions In West Nile, we found that clothianidin-based IRS (plus ITNs) did not reduce malaria incidence, while a subsequent round of IRS with pirimiphos-methyl (plus ITNs), 1 year after clothianidin-deltamethrin, substantially reduced malaria incidence as compared to ITNs alone in the neighbouring Acholi region. Whilst periodic IRS insecticide rotation is a pragmatic approach to resistance management, it is only useful if the replacement insecticide is equally effective. Our findings underscore the need to assess wild vector susceptibility to insecticides prior to implementing large-scale vector control measures in endemic settings. Evaluating insecticides in real-world settings remains a priority, rather than relying solely on modelling or experimental hut trials. Organophosphates may be preferred over clothianidin-based insecticides for population-level IRS coverage in similar settings. Continued entomological and epidemiological monitoring of IRS impact and for signals of resistance to both organophosphates and neonicotinoids is warranted. Malaria vector control programmes should be guided by context-specific data on insecticide effectiveness. The synergistic effect of dual interventions should be considered in areas of high pyrethroid resistance. Supplementary Information Supplementary material 1: Supplementary table (Table S1) which shows the types, coverage, and deployment dates for LLINs and IRS for each study site; Fig. S1, a map showing the target area for Opia HCIII – Arua district; Fig. S2, showing trends in site-specific outpatient visits, non-malarial visits, malaria confirmatory testing and RDT testing stratified by study arm; Fig. S3, showing trends in mean TPR and mean incidence by study arm, with Fig. S3A showing trends in mean incidence in the control arm (left) and intervention arm (right), and Fig. S3B showing trends in mean TPR in the control arm (left) and intervention arm (right); and Fig. S4 showing trends in mean incidence of care-seeking for non-malarial illnesses and mean rainfall within target areas stratified by study arm. Supplementary material 2: The Transparent Reporting of Evaluations with Nonrandomized Designs (TREND) checklist for this paper. Acknowledgements The authors thank members of the UMSP core surveillance team at IDRC, healthcare workers at public health facilities with ongoing MRC surveillance activities, district local government officials at respective districts in Uganda, and government officials at the Ministry of Health Uganda National Malaria Elimination Division. Abbreviations Adjusted incidence rate ratio Centre for Disease Control Dichloro-diphenyl-trichloroethane Difference-in-difference Enhanced Entomological Surveillance Health Management Information System Infectious Diseases Research Collaboration Incidence rate ratio Indoor residual spraying of insecticide Insecticide-treated nets Long-lasting insecticidal nets Malaria reference centre Piperonyl butoxide Program for Resistance, Immunology, Surveillance and Modelling of Malaria Standard deviation Test positivity rate World Health Organisation Authors’ contributions JFN: conceptualisation, methodology, formal analysis, investigation, data curation, writing—original draft, writing—review and editing, visualisation, and project administration; DPM: methodology, formal analysis, data curation, writing—review and editing, and visualisation; AE: methodology, formal analysis, writing—review and editing, data curation, and visualisation; JIN: writing—review and editing, securing funding, project administration; SG: writing—review and editing, project administration; JO: project administration; IN: investigation, data curation; CMS: writing—review and editing, project administration; MRK: writing—review and editing, project administration, securing funding and supervision; MJD: conceptualisation, methodology, writing—review and editing, securing funding, and supervision; GD: conceptualisation, methodology, investigation, data curation, writing—review and editing, supervision, and securing funding; and SGS: conceptualisation, methodology, investigation, writing—review and editing, supervision, securing funding, and project administration. All authors read and approved the final manuscript. Funding Funding for all research-related activities was provided by the National Institutes of Health as part of the International Centres of Excellence in Malaria Research (ICEMR) programme (U19AI089674), and the Commonwealth Scholarship Commission (CSC) in the UK, under the Commonwealth Scholarship Commission. More information can be found at https://cscuk.fcdo.gov.uk. Data availability The datasets and analytic codes supporting the conclusions of this article is(are) available in a GitHub repository UMSP-West-Nile-Project [36]. https://github.com/Jennyfnm/WestNile-IRS-Project. Declarations Ethical approval and consent to participate Ethical approval to conduct this study was sought from Makerere University College of Health Sciences School of Public Health Research and Ethics Committee (SPHREC) in Uganda, approval number SPH-2025-551, and the University of California, San Francisco Ethics Committee, IRB number 24-41185, and reference number 460466. Waiver of informed consent was granted for this study by SPHREC because the study involved extraction of secondary data from patient records without using any personal identifiers. This research conformed to the principles of the Helsinki Declaration. Competing interests AE is the guest editor for the collection ‘Advances in malaria control and elimination’ at BMC Global and Public Health. The remaining authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary material 1: Supplementary table (Table S1) which shows the types, coverage, and deployment dates for LLINs and IRS for each study site; Fig. S1, a map showing the target area for Opia HCIII – Arua district; Fig. S2, showing trends in site-specific outpatient visits, non-malarial visits, malaria confirmatory testing and RDT testing stratified by study arm; Fig. S3, showing trends in mean TPR and mean incidence by study arm, with Fig. S3A showing trends in mean incidence in the control arm (left) and intervention arm (right), and Fig. S3B showing trends in mean TPR in the control arm (left) and intervention arm (right); and Fig. S4 showing trends in mean incidence of care-seeking for non-malarial illnesses and mean rainfall within target areas stratified by study arm. Supplementary material 2: The Transparent Reporting of Evaluations with Nonrandomized Designs (TREND) checklist for this paper. Data Availability Statement The datasets and analytic codes supporting the conclusions of this article is(are) available in a GitHub repository UMSP-West-Nile-Project [36]. https://github.com/Jennyfnm/WestNile-IRS-Project.